BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11830487)

  • 1. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
    Zhou DC; Kim SH; Ding W; Schultz C; Warrell RP; Gallagher RE
    Blood; 2002 Feb; 99(4):1356-63. PubMed ID: 11830487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
    Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
    Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
    Jing Y; Xia L; Waxman S
    Blood; 2002 Aug; 100(3):1008-13. PubMed ID: 12130515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
    Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
    Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia.
    Takayama N; Kizaki M; Hida T; Kinjo K; Ikeda Y
    Exp Hematol; 2001 Jul; 29(7):864-72. PubMed ID: 11438209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
    Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
    Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
    Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
    Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia.
    Kitamura K; Kiyoi H; Yoshida H; Saito H; Ohno R; Naoe T
    Leukemia; 1997 Nov; 11(11):1950-6. PubMed ID: 9369431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
    Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
    Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies.
    Petti MC; Fazi F; Gentile M; Diverio D; De Fabritiis P; De Propris MS; Fiorini R; Spiriti MA; Padula F; Pelicci PG; Nervi C; Lo Coco F
    Blood; 2002 Aug; 100(3):1065-7. PubMed ID: 12130525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
    Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
    Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.
    Kitareewan S; Pitha-Rowe I; Sekula D; Lowrey CH; Nemeth MJ; Golub TR; Freemantle SJ; Dmitrovsky E
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3806-11. PubMed ID: 11891284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
    Guo Y; Dolinko AV; Chinyengetere F; Stanton B; Bomberger JM; Demidenko E; Zhou DC; Gallagher R; Ma T; Galimberti F; Liu X; Sekula D; Freemantle S; Dmitrovsky E
    Cancer Res; 2010 Dec; 70(23):9875-85. PubMed ID: 20935222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.
    Zhong S; Delva L; Rachez C; Cenciarelli C; Gandini D; Zhang H; Kalantry S; Freedman LP; Pandolfi PP
    Nat Genet; 1999 Nov; 23(3):287-95. PubMed ID: 10610177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the histone deacetylase complex in acute promyelocytic leukaemia.
    Lin RJ; Nagy L; Inoue S; Shao W; Miller WH; Evans RM
    Nature; 1998 Feb; 391(6669):811-4. PubMed ID: 9486654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.
    Benedetti L; Grignani F; Scicchitano BM; Jetten AM; Diverio D; Lo Coco F; Avvisati G; Gambacorti-Passerini C; Adamo S; Levin AA; Pelicci PG; Nervi C
    Blood; 1996 Mar; 87(5):1939-50. PubMed ID: 8634442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.